Cargando…

Pre-lymphodepletion & infusion endothelial activation and stress index as predictors of clinical outcomes in CAR-T therapy for B-cell lymphoma

Detalles Bibliográficos
Autores principales:	Acosta-Medina, Aldo A., Johnson, Isla McKerrow, Bansal, Radhika, Hathcock, Matthew, Kenderian, Saad J., Durani, Urshila, Khurana, Arushi, Wang, Yucai, Paludo, Jonas, Villasboas, Jose C., Bennani, N. Nora, Johnston, Patrick B., Ansell, Stephen M., Lin, Yi, Alkhateeb, Hassan B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813206/ https://www.ncbi.nlm.nih.gov/pubmed/36599834 http://dx.doi.org/10.1038/s41408-022-00777-4

Ejemplares similares

Metabolic PET/CT analysis of aggressive Non-Hodgkin lymphoma prior to Axicabtagene Ciloleucel CAR-T infusion: predictors of progressive disease, survival, and toxicity
por: Breen, William G., et al.
Publicado: (2023)

The impact of obesity and body weight on the outcome of patients with relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel
por: Wudhikarn, Kitsada, et al.
Publicado: (2021)

Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET/CT
por: Breen, William G., et al.
Publicado: (2022)

Procalcitonin as a biomarker for predicting bacterial infection in chimeric antigen receptor T‐cell therapy recipients
por: Powell, Marissa Z., et al.
Publicado: (2023)

Barriers to enrollment in clinical trials of patients with aggressive B-cell NHL that progressed after CAR T-cell therapy
por: Bezerra, Evandro D., et al.
Publicado: (2022)

Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma
por: Wiedmeier, Julia E., et al.
Publicado: (2021)

Consolidative radiotherapy for residual fluorodeoxyglucose activity on day +30 post CAR T-cell therapy in non-Hodgkin lymphoma
por: Saifi, Omran, et al.
Publicado: (2023)

Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma
por: Wiedmeier-Nutor, Julia E., et al.
Publicado: (2023)

S263: CYTOPENIAS, AGE AND CAR-HEMATOTOX SCORE PREDICT THE DEVELOPMENT OF POST CAR T-CELL THERAPY-RELATED MYELOID NEOPLASMS
por: Gurney, Mark, et al.
Publicado: (2023)

Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma
por: Alkhateeb, Hassan B., et al.
Publicado: (2022)

Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy
por: Fabrizio, Vanessa A., et al.
Publicado: (2022)

Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma
por: Wiedmeier-Nutor, Julia Erin, et al.
Publicado: (2022)

P1359: TUMOR-SPECIFIC, T-CELL-TARGETING MICRORNA IS ASSOCIATED WITH CART CELL FAILURE IN B CELL MALIGNANCIES
por: Chohan, Karan, et al.
Publicado: (2023)

Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma
por: Suryadevara, Carter M., et al.
Publicado: (2018)

Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma
por: Sidana, Surbhi, et al.
Publicado: (2023)

Peripheral blood cellular profile at pre-lymphodepletion is associated with CD19-targeted CAR-T cell-associated neurotoxicity
por: De Matteis, Serena, et al.
Publicado: (2023)

Case Report: Lymphodepletion followed by CAR-T cell therapy with Idecabtagen vicleucel in a patient with severe renal impairment
por: Marquard, Franziska, et al.
Publicado: (2023)

Lymphodepleting chemotherapy with donor lymphocyte infusion post-allogeneic HCT for hematological malignancies is associated with severe, but therapy-responsive aGVHD
por: He, Fiona, et al.
Publicado: (2016)

Efficacy and safety of humanized anti‐CD19‐CAR‐T therapy following intensive lymphodepleting chemotherapy for refractory/relapsed B acute lymphoblastic leukaemia
por: Wang, Jia, et al.
Publicado: (2020)

P1394: RITUXIMAB BASED LYMPHODEPLETION MAY INCREASE ENGRAFTMENT AND EFFICACY OF SECOND INFUSIONS OF CART19 CELLS IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA.
por: Ortiz-Maldonado, Valentín, et al.
Publicado: (2023)

World Class Parasites: Vol. X, Schistosomiasis
por: McKerrow, James
Publicado: (2006)

Trends in medical students’ stress, physical, and emotional health throughout training
por: McKerrow, Isla, et al.
Publicado: (2020)

Introduction to robotics /
por: McKerrow, Phillip, 1949-
Publicado: (1991)

Designing Drugs for Parasitic Diseases of the Developing World
por: McKerrow, James H
Publicado: (2005)

The diverse roles of cysteine proteases in parasites and their suitability as drug targets
por: McKerrow, James H.
Publicado: (2018)

Update on drug development targeting parasite cysteine proteases
por: McKerrow, James H.
Publicado: (2018)

Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy
por: Nissani, Abraham, et al.
Publicado: (2021)

Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era
por: Arushi Khurana, et al.
Publicado: (2021)

Infection Complications after Lymphodepletion and Dosing of Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia or B Cell Non-Hodgkin Lymphoma
por: Korell, Felix, et al.
Publicado: (2021)

Long‐term outcome of immunologic autograft engineering
por: Porrata, Luis F., et al.
Publicado: (2022)

Epithelioid angiosarcoma: A rare cause of pericarditis and pleural effusion
por: Durani, Urshila, et al.
Publicado: (2018)

Selective CD28 blockade impacts T cell differentiation during homeostatic reconstitution following lymphodepletion
por: Habib, Jakob G., et al.
Publicado: (2023)

Frontline polatuzumab vedotin for diffuse large B‐cell lymphoma: A survey of clinician impressions
por: Major, Ajay, et al.
Publicado: (2022)

Editorial: Drug Development for Parasite-Induced Diarrheal Diseases
por: Debnath, Anjan, et al.
Publicado: (2017)

The feasibility and ongoing use of electronic decision support to strengthen the implementation of IMCI in KwaZulu-Natal, South Africa
por: Jensen, Cecilie, et al.
Publicado: (2022)

Recent advances in the management of Hodgkin lymphoma
por: Villasboas, Jose C., et al.
Publicado: (2016)

P53. Effect of lymphodepletion and tumour on host and reconstituted regulatory T-cells in a model of murine melanoma
por: Kovács, J, et al.
Publicado: (2014)

Decitabine in combination with fludarabine and cyclophosphamide as a lymphodepletion regimen followed by CD19/CD22 bispecific targeted CAR T-cell therapy significantly improves survival in relapsed/refractory B-ALL patients
por: Ma, Yunju, et al.
Publicado: (2023)

Fabrizio VA, Boelens JJ, Mauguen A, et al. Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. Blood Adv. 2022;6(7):1961-1968.
Publicado: (2023)

The rule of five should not impede anti-parasitic drug development
por: McKerrow, James H., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_6h69udobflcsssnhqf2k2io68c